Table 6 Post-operative evaluation
Parameter | N = 2013 |
|---|---|
TNM staging (AJCC seventh edition), n (%) | 2013 |
 I | 1313 (65.2) |
 II | 16 (0.8) |
 III | 336 (16.7) |
 IV A | 342 (17.0) |
 IV B | 1 (0.0) |
 IV C | 5 (0.2) |
TNM staging (AJCC eight edition), n (%) | 2011 |
 I | 1845 (91.7) |
 II | 135 (6.7) |
 III | 31 (1.5) |
 Missing | 2 (0.1) |
Recurrence risk stratification, n (%) | 2013 |
 Intermediate | 1528 (75.9) |
 High | 485 (24.1) |
Side-effect risk stratification for TSH suppression therapy, n (%) | 1984 |
 Low | 1109 (55.9) |
 Intermediate | 640 (32.3) |
 High | 235 (11.8) |
 Missing | 29 (1.5) |